Kavar Capital Partners Group LLC cut its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 1.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,628 shares of the medical instruments supplier’s stock after selling 410 shares during the period. Becton, Dickinson and Company comprises 1.2% of Kavar Capital Partners Group LLC’s portfolio, making the stock its 23rd biggest position. Kavar Capital Partners Group LLC’s holdings in Becton, Dickinson and Company were worth $7,626,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Kingswood Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $229,000. Vicus Capital purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $601,000. Red Door Wealth Management LLC increased its holdings in shares of Becton, Dickinson and Company by 3.7% in the 1st quarter. Red Door Wealth Management LLC now owns 1,437 shares of the medical instruments supplier’s stock valued at $356,000 after acquiring an additional 51 shares during the period. BKM Wealth Management LLC increased its holdings in shares of Becton, Dickinson and Company by 17.1% in the 1st quarter. BKM Wealth Management LLC now owns 4,891 shares of the medical instruments supplier’s stock valued at $1,210,000 after acquiring an additional 715 shares during the period. Finally, Claro Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 26.5% in the 1st quarter. Claro Advisors LLC now owns 2,852 shares of the medical instruments supplier’s stock valued at $706,000 after acquiring an additional 597 shares during the period. 86.97% of the stock is owned by institutional investors.
Becton, Dickinson and Company Stock Performance
NYSE BDX opened at $238.13 on Friday. The stock has a market capitalization of $68.82 billion, a price-to-earnings ratio of 52.45, a PEG ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $259.92. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The stock has a 50-day moving average of $237.46 and a 200 day moving average of $235.08.
Analysts Set New Price Targets
BDX has been the topic of a number of analyst reports. Raymond James cut their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI boosted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $282.63.
Check Out Our Latest Analysis on Becton, Dickinson and Company
Becton, Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
See Also
- Five stocks we like better than Becton, Dickinson and Company
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is a support level?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.